- A New Roadmap for Optimizing Thiopurine Therapy in Acute Lymphocytic LeukemiaJanuary 11, 2016 | Elizabeth Raetz, MD | Julia Meyer, PhD
Drs. Raetz and Meyer highlight advances in the field of pediatric acute lymphocytic leukemia (ALL), keeping in mind that there is still much to learn regarding the most effective and safe method for delivering conventional chemotherapeutic drugs.
- Acquired Aplastic Anemia: Somatic Mutations and Eltrombopag Take the SpotlightJanuary 11, 2016 | Tracy I. George, MD | Melody Harrison, MD
Drs. George and Harrison discuss the progress made during 2015 in the field of acquired aplastic anemia (AA).
- Clinical Implications of Novel Regulatory Mechanisms for Production of Platelets, Neutrophils, and ErythrocytesJanuary 11, 2016 | Mark J. Koury, MD
Dr. Koury reviews several publications that have advanced our understanding of steady-state and emergency production rates for platelets, neutrophils, and erythrocythes.
- Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander?January 11, 2016 | Pamela S. Becker, MD, PhD
Dr. Becker studies clonal hematopoiesis and how somatic cells may contribute to clonal expansion and development of myeloid neoplasms with the acquisition of additional cooperating mutations.
- Flipping a Switch: Advances in DOAC Reversal in 2015January 11, 2016 | Adam Cuker, MD, MS
Dr. Cuker discusses the continuous progress in the field of direct oral anticoagulants (DOAC) by looking at two studies that test the efficacy and safety of idarucizumab and andexanet alfa in patients with DOAC-associated bleeding.
- Malaria: Progress in the Host-Pathogen Arms RaceJanuary 11, 2016 | Theresa Coetzer, PhD
Dr. Coetzer looks at advancements in the discovery of new therapies to treat malaria. She reviews four studies that show major developments in battling this pathogen and highlights several challenges that remain to ensure that current progress in this battle is not lost.
- New Therapeutic Frontiers in Sickle Cell DiseaseJanuary 11, 2016 | Charles T. Quinn, MD, MS
Dr. Quinn looks at progress made in the field of sickle cell disease (SCD) including an array of potential new therapies.
- Novel Drugs Push the Envelope in Multiple MyelomaJanuary 11, 2016 | Andrew J. Yee, MD | Elizabeth O'Donnell, MD | Noopur Raje, MD
Drs. Raje, O'Donnell, and Yee discuss progress in drugs for the treatment of multiple myeloma, especially immuno-oncology and monoclonal antibodies (MoABs).
- Practice-Defining Clinical Trials in Nonmalignant HematologyJanuary 11, 2016 | David Garcia, MD
Dr. Garcia discusses trials in the past year that invalidated two myths regarding nonmalignant hematology.
- Therapeutically Enhancing Stem Cell EngraftmentJanuary 11, 2016 | Jonathan Hoggatt, PhD
Dr. Hoggatt sheds light on several studies carried out in 2015 that have begun supporting potential therapies to enhance stem cell engraftment.
- Using Interim PET to Direct Therapy for Early Hodgkin Lymphoma: Results from the TrialsJanuary 11, 2016 | Ann S. LaCasce, MD, MSc | Peter Johnson, MD
Drs. Johnson and LaCasce look at several trials that used interim positron emission tomography (PET) scanning to determine efficacy of treatment of Hodgkin lymphoma (HL).
- What We Carried on Christmas: Fiction for the Year's Best in HematologyJanuary 11, 2016 | Jason Gotlib, MD, MS
In this fiction piece, Dr. Gotlib provides his perspective on how hematology advances, including 2015 Year's Best selections, weave together with the compelling narratives of patients' lives.